Abbott Laboratories vs Adaptyv Biosystems

Side-by-side comparison of AI visibility scores, market position, and capabilities

Abbott Laboratories leads in AI visibility (86 vs 24)

Abbott Laboratories

LeaderHealthcare

General

Diversified healthcare company with $20-22B revenue; FreeStyle Libre CGM, cardiovascular devices, and diagnostics across medical devices, nutrition, and pharma.

AI VisibilityBeta
Overall Score
A86
Category Rank
#47 of 1167
AI Consensus
61%
Trend
stable
Per Platform
ChatGPT
89
Perplexity
92
Gemini
95

About

Abbott Laboratories is a diversified global healthcare company operating across diagnostics, medical devices, nutritional products, and established pharmaceuticals in over 160 countries. Founded in 1888 by Dr. Wallace Calvin Abbott in Chicago, Illinois and listed on the NYSE, Abbott generates approximately $20-22 billion in annual revenue and employs over 100,000 people globally. The company's portfolio spans four major segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals.

Full profile

Adaptyv Biosystems

EmergingHealthcare

General

Lausanne Switzerland automated cloud lab for AI protein engineering at $11.2M total ($8M ACE Ventures seed 2025); improved protein success rate from 2.5% to 13% testing 10K+ proteins for 30+ pharma/biotech partners competing with Recursion for AI drug discovery.

AI VisibilityBeta
Overall Score
D24
Category Rank
#995 of 1167
AI Consensus
74%
Trend
stable
Per Platform
ChatGPT
21
Perplexity
21
Gemini
29

About

Adaptyv Biosystems is a Lausanne, Switzerland-based AI-driven protein engineering platform — backed with $11.2 million in total funding including an $8 million seed round in 2025 led by ACE Ventures with participation from ByFounders, Founderful, and LongGame Ventures, following a CHF 2.5 million pre-seed in 2022 — providing pharmaceutical companies, biotechnology firms, and academic AI research groups with fully automated cloud laboratory services for validating and iterating AI-generated protein designs, enabling the experimental testing that transforms computational protein engineering from theoretical exploration to practical drug discovery. Founded in 2021 and having tested over 10,000 proteins in collaboration with 30+ pharma and biotech partners, Adaptyv has improved protein engineering success rates from the industry baseline of 2.5% to 13% — a 5x improvement that represents the breakthrough enabling practical AI-guided therapeutic protein development.

Full profile

AI Visibility Head-to-Head

86
Overall Score
24
#47
Category Rank
#995
61
AI Consensus
74
stable
Trend
stable
89
ChatGPT
21
92
Perplexity
21
95
Gemini
29
78
Claude
22
86
Grok
17

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.